<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-37693" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ergotamine/Caffeine </title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ngo </surname>
            <given-names>Michelle</given-names>
          </name>
          <aff>Creighton University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tadi</surname>
            <given-names>Prasanna</given-names>
          </name>
          <aff>Asram Medical College, Eluru, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michelle Ngo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prasanna Tadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-37693.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">The combination of ergotamine and caffeine is a medication used in the management and treatment of acute migraines. It is in the ergot alkaloid class of drugs. This article outlines the indications, action, and contraindications for Ergotamine/caffeine as a valuable agent in the treatment of acute migraines. This article will highlight the mechanism of action, adverse event profile, and other key factors, including dosing, pharmacokinetics, monitoring, and relevant interactions pertinent for members of the interprofessional healthcare team in the care of patients with acute migraines and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for ergotamine/caffeine administration.</p></list-item><list-item><p>Describe the mechanism of action of ergotamine/caffeine.</p></list-item><list-item><p>Summarize the adverse effects and contraindications of ergotamine/caffeine.</p></list-item><list-item><p>Explain the importance of implementing a multidisciplinary approach in the delivery of care for patients with migraine headaches.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37693&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37693">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-37693.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Ergotamine/caffeine, also known as ergotamine tartrate, is FDA approved to terminate or prevent vascular headaches such as migraines, variations of migraines, or cluster headaches. Since this is a migraine-specific agent, it is for use in patients who present with more severe symptoms and whose migraines have not responded to NSAIDs or combination analgesics. Additionally, because there are other medication options for the acute treatment of migraines that have fewer side effects, it is recommended that clinicians weigh the options and only prescribe ergotamine/caffeine to patients with attacks greater than 48 hours or frequent headache recurrence.&#x000a0;Ergotamine/caffeine is also indicated for autonomic failure because it improves seated blood pressure and presyncopal symptoms; this is not an FDA approved indication.<xref ref-type="bibr" rid="article-37693.r1">[1]</xref><xref ref-type="bibr" rid="article-37693.r2">[2]</xref><xref ref-type="bibr" rid="article-37693.r3">[3]</xref></p>
      </sec>
      <sec id="article-37693.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Although the cause of migraine headaches is not entirely understood, the thinking is that arteriolar vasodilation and inflammation of the trigeminal nerve due to the release of local vasoactive peptides, such as 5-hydroxytryptamine (5-HT) and calcitonin gene-related protein (CGRP) plays a role. CGRP is a neuropeptide that can be found in the central and peripheral nervous systems and has pain-signaling and vasodilator functions. Patients with migraines have elevated levels of circulating CGRP, and migraine medications, such as the ergot alkaloids, are associated with lowering these CGRP levels.<xref ref-type="bibr" rid="article-37693.r2">[2]</xref><xref ref-type="bibr" rid="article-37693.r4">[4]</xref>&#x000a0;Ergotamine has a complex mechanism of action that involves a variety of receptors, including 5-HT-1B/1D, dopamine, and alpha-adrenoreceptors. By activating 5HT-1B and 5HT-1D receptors on intracranial blood vessels, ergotamine induces vasoconstriction and relief of migraine headaches. Ergotamine also inhibits norepinephrine uptake and stimulates alpha-adrenergic receptors at therapeutic doses, leading to prolonged vasoconstriction. Blood flow to the extremities thus becomes reduced.<xref ref-type="bibr" rid="article-37693.r5">[5]</xref></p>
        <p>Caffeine may work synergistically with ergotamine by also constricting cerebral vasculature or enhancing its GI absorption. The vasoconstrictive effects of caffeine are due to its antagonistic properties at adenosine A1, A2A, and A2B receptors. Implications point to adenosine receptors in vasodilation. The mechanism of&#x000a0;caffeine's rate-accelerating effect appears to be due to its ability to increase ergotamine's water solubility and decrease gastric pH. Caffeine also has numerous physiologic effects that may influence improvement in migraine symptoms such as enhancing mood, alertness, and exercise performance.<xref ref-type="bibr" rid="article-37693.r6">[6]</xref><xref ref-type="bibr" rid="article-37693.r7">[7]</xref><xref ref-type="bibr" rid="article-37693.r8">[8]</xref></p>
      </sec>
      <sec id="article-37693.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Ergotamine/caffeine has several various formulations, including aerosol, oral, and suppository, though the aerosol form is slowly being withdrawn from the market. It is available in 1 mg (ergotamine)+100 mg (caffeine) tablets under multiple brand names. It is also available as 2 mg rectal suppositories or a 2 mg sublingual form. Ergotamine/caffeine should be administered orally or sublingually for a slowly developing migraine that does not present with early-onset nausea and for treating cluster headaches. At the first sign of a migraine, the patient can place one 2 mg tablet under the tongue, and another tablet should be taken at 30-minute intervals following the initial tablet, if necessary.<bold>&#x000a0;</bold>For severe and rapid onset migraines with nausea and/or vomiting, ergotamine should be administered via rectal suppository in combination with caffeine, as this is the most effective form.<xref ref-type="bibr" rid="article-37693.r9">[9]</xref><xref ref-type="bibr" rid="article-37693.r10">[10]</xref><xref ref-type="bibr" rid="article-37693.r11">[11]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-37693.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Because ergotamine is not specific for the 5HT-1 serotonin receptors, it can cause a broad range of side effects. A common side effect of ergotamine and caffeine use is nausea and vomiting after both oral and parenteral administration, most likely due to a direct impact on CNS emetic centers. Cramps, insomnia, and transient lower limb muscle pain can also occur.<xref ref-type="bibr" rid="article-37693.r12">[12]</xref>&#x000a0;Other adverse effects of ergotamine tartrate that are related to excessive dosage or chronic usage include ischemia, overuse headache, acroparesthesia, and ergotism.<xref ref-type="bibr" rid="article-37693.r13">[13]</xref> Bocchia et al. reported a case of chronic intoxication (ergotism), similar to the effects of ingesting Claviceps purpurea-infected rye, after ergotamine tartrate administration. The patient had been administered ergotamine rectally for her chronic migraine and showed signs of cerebral and leg ischemia due to vasospasm of the carotid and femoral arteries. Stopping the drug led to complete remission of the symptoms.<xref ref-type="bibr" rid="article-37693.r14">[14]</xref> Aabech et al. also reported 14 cases of severe ischemia in the extremities due to ergotism.<xref ref-type="bibr" rid="article-37693.r15">[15]</xref> Ergotamine-induced rectal lesions, though rare, can also be a complication that warrants alternative routes of administration if ergotamine use will be long-term.<xref ref-type="bibr" rid="article-37693.r16">[16]</xref> Reports also exist of myocardial infarction and fibrotic changes as adverse effects.<xref ref-type="bibr" rid="article-37693.r17">[17]</xref>&#x000a0;Perez et al. reported a case of a patient with an ST-segment elevation myocardial infarct due to chronic ergotamine use, though these events are very rare.<xref ref-type="bibr" rid="article-37693.r18">[18]</xref></p>
      </sec>
      <sec id="article-37693.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Ergotamine tartrate/caffeine is contraindicated in patients with peripheral vascular disorders, coronary artery disease, stroke, uncontrolled hypertension, impaired renal or hepatic function, sepsis, and pregnancy due to its vasoconstrictor effect. Additionally, because ergotamine metabolism occurs through cytochrome P450 (CYP) 3A4 in the liver, it is contraindicated in patients taking medications that are CYP 3A4 inhibitors since these would slow the metabolism of ergotamine and cause toxic effects such as stroke, gangrene, or death. Such CYP 3A4 inhibitors include grapefruit juice, heparin, tacrolimus, cyclosporine, ampicillin, macrolide antibiotics, antifungals, protease inhibitors, and antidepressants.<xref ref-type="bibr" rid="article-37693.r19">[19]</xref><xref ref-type="bibr" rid="article-37693.r20">[20]</xref></p>
      </sec>
      <sec id="article-37693.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Bioavailability of ergotamine/caffeine is about 5% or less through oral and rectal administration. One study estimated that the maximal possible bioavailability for tablets was 2% and for suppositories was 5%.<xref ref-type="bibr" rid="article-37693.r21">[21]</xref>&#x000a0;The elimination half-life is 2 to 2.5 hours, and clearance is approximately 0.68 L/h/kg. Ergotamine/caffeine should be administered as a 2 mg dose initially, and if symptoms persist, continue with 1 to 2 mg every 30 minutes. However, the maximum dosage should be 6 mg per attack and 10 mg weekly.<xref ref-type="bibr" rid="article-37693.r9">[9]</xref></p>
      </sec>
      <sec id="article-37693.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Ergotamine poisoning and overdose symptoms are rarely seen in today&#x02019;s clinical practice because newer, safer anti-migraine medications such as triptans are used more widely due to fewer side effects. However, intoxication symptoms could still manifest in sensitive patients taking it for migraine relief. In such cases, treatment involves the initial withdrawal of the drug, which could relieve symptoms. One study also noted that sodium nitroprusside administered intravenously, along with low molecular weight Dextran and Heparin, was successful in treating ergotamine poisoning.<xref ref-type="bibr" rid="article-37693.r22">[22]</xref><xref ref-type="bibr" rid="article-37693.r14">[14]</xref><xref ref-type="bibr" rid="article-37693.r23">[23]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-37693.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>It is important to approach headache treatment from a multidisciplinary perspective by employing various strategies to treat and educate patients about handling their pain to enhance the quality of life. Pharmacists, neurologists, psychologists, and physical therapists all play an important role in managing patient headaches and reducing the risk of medication overuse. Pharmacotherapy may be acute or preventative, and the prescriber must be fully aware of the possible side effects of ergotamine and what adverse reactions it could have if taken with other drugs. Since the introduction of more selective drugs with fewer side effects, such as the triptans, physicians must also exercise sound clinical judgment and effective communication with the healthcare team to evaluate the various medication options. Numerous authors have compared the efficacy and safety of triptans versus ergot alkaloids for the treatment of acute migraines and came to mixed conclusions. Thus, the physician needs to discuss with the pharmacy team what options might be best for individual patients.<xref ref-type="bibr" rid="article-37693.r24">[24]</xref><xref ref-type="bibr" rid="article-37693.r25">[25]</xref><xref ref-type="bibr" rid="article-37693.r26">[26]</xref>&#x000a0;</p>
        <p>Psychologists can carry out education and cognitive behavioral therapy for migraine patients, including self-management, handling medication, and lifestyle education. Physical therapists play a supplementary role in preventing headache episodes because of the common coexistence of neck pain with headaches. Additionally, various types of relaxation training can be effective treatments in preventing migraines. Due to the pervasive nature of migraines and the complexity of their treatment, it is valuable to utilize a multidisciplinary approach to achieve the most effective outcomes for the patient.<xref ref-type="bibr" rid="article-37693.r27">[27]</xref><xref ref-type="bibr" rid="article-37693.r28">[28]</xref>&#x000a0;[Level V]</p>
      </sec>
      <sec id="article-37693.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37693&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37693">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/37693/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=37693">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-37693.s11">
        <title>References</title>
        <ref id="article-37693.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tfelt-Hansen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saxena</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Dahl&#x000f6;f</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>L&#x000e1;inez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Diener</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schoenen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Ergotamine in the acute treatment of migraine: a review and European consensus.</article-title>
            <source>Brain</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>123 ( Pt 1)</volume>
            <fpage>9</fpage>
            <page-range>9-18</page-range>
            <pub-id pub-id-type="pmid">10611116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <chapter-title>Migraine Headache Agents</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>7</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">31643527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnold</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Ramirez</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Okamoto</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Gamboa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Diedrich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Raj</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Biaggioni</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Shibao</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Combination ergotamine and caffeine improves seated blood pressure and presyncopal symptoms in autonomic failure.</article-title>
            <source>Front Physiol</source>
            <year>2014</year>
            <volume>5</volume>
            <fpage>270</fpage>
            <pub-id pub-id-type="pmid">25104940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis.</article-title>
            <source>J Headache Pain</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>42</fpage>
            <pub-id pub-id-type="pmid">28389966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>McCrory</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.</article-title>
            <source>Headache</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>43</volume>
            <issue>2</issue>
            <fpage>144</fpage>
            <page-range>144-66</page-range>
            <pub-id pub-id-type="pmid">12558771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Drehsen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pitman</surname>
                <given-names>IH</given-names>
              </name>
            </person-group>
            <article-title>Effect of caffeine on ergotamine absorption from rat small intestine.</article-title>
            <source>J Pharm Sci</source>
            <year>1981</year>
            <month>Jun</month>
            <volume>70</volume>
            <issue>6</issue>
            <fpage>651</fpage>
            <page-range>651-7</page-range>
            <pub-id pub-id-type="pmid">7252810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Reches</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pitei</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>TJ</given-names>
              </name>
              <collab>Eletriptan and Cafergot Comparative Study Group</collab>
            </person-group>
            <article-title>Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison.</article-title>
            <source>Eur Neurol</source>
            <year>2002</year>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-107</page-range>
            <pub-id pub-id-type="pmid">11844898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Garas</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Caffeine in the management of patients with headache.</article-title>
            <source>J Headache Pain</source>
            <year>2017</year>
            <month>Oct</month>
            <day>24</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>107</fpage>
            <pub-id pub-id-type="pmid">29067618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <chapter-title>Ergot Alkaloids</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>2</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31643724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathew</surname>
                <given-names>NT</given-names>
              </name>
            </person-group>
            <article-title>Dosing and administration of ergotamine tartrate and dihydroergotamine.</article-title>
            <source>Headache</source>
            <year>1997</year>
            <volume>37 Suppl 1</volume>
            <fpage>S26</fpage>
            <page-range>S26-32</page-range>
            <pub-id pub-id-type="pmid">9009471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ekbom</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Krabbe</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Paalzow</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Paalzow</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tfelt-Hansen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Waldenlind</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Optimal routes of administration of ergotamine tartrate in cluster headache patients. A pharmacokinetic study.</article-title>
            <source>Cephalalgia</source>
            <year>1983</year>
            <month>Mar</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-20</page-range>
            <pub-id pub-id-type="pmid">6406071</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antonaci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ghiotto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pucci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in migraine therapy.</article-title>
            <source>Springerplus</source>
            <year>2016</year>
            <volume>5</volume>
            <fpage>637</fpage>
            <pub-id pub-id-type="pmid">27330903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.</article-title>
            <source>Headache</source>
            <year>1997</year>
            <volume>37 Suppl 1</volume>
            <fpage>S33</fpage>
            <page-range>S33-41</page-range>
            <pub-id pub-id-type="pmid">9009472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bocchia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baldini</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Bertola</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zorzoli</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>[Risks related to the use of ergotamine in the therapy of hemicrania. Description of a case].</article-title>
            <source>Recenti Prog Med</source>
            <year>1991</year>
            <season>Jul-Aug</season>
            <volume>82</volume>
            <issue>7-8</issue>
            <fpage>390</fpage>
            <page-range>390-3</page-range>
            <pub-id pub-id-type="pmid">1947404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aabech</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Engell</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>[Ergotism in migraine. Peripheral vascular complications in 14 patients with migraine].</article-title>
            <source>Ugeskr Laeger</source>
            <year>1989</year>
            <month>Aug</month>
            <day>14</day>
            <volume>151</volume>
            <issue>33</issue>
            <fpage>2067</fpage>
            <page-range>2067-70</page-range>
            <pub-id pub-id-type="pmid">2773132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jost</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Schimrigk</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>[Ergotamine-induced rectal lesions in asymptomatic patients].</article-title>
            <source>Wien Klin Wochenschr</source>
            <year>1994</year>
            <volume>106</volume>
            <issue>6</issue>
            <fpage>171</fpage>
            <page-range>171-3</page-range>
            <pub-id pub-id-type="pmid">8197748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyler</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Side effects of ergotamine.</article-title>
            <source>Cephalalgia</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-10</page-range>
            <pub-id pub-id-type="pmid">8825693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000e9;rez Baztarrica</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Armijos Carrion</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Abarca Real</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Paredes Lima</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Giler Saltos</surname>
                <given-names>OP</given-names>
              </name>
              <name>
                <surname>Porcile</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Acute coronary syndrome with elevation of ST associated with ergotamine abuse.</article-title>
            <source>Rom J Intern Med</source>
            <year>2019</year>
            <month>Mar</month>
            <day>01</day>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-71</page-range>
            <pub-id pub-id-type="pmid">30954974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wooltorton</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Risk of stroke, gangrene from ergot drug interactions.</article-title>
            <source>CMAJ</source>
            <year>2003</year>
            <month>Apr</month>
            <day>15</day>
            <volume>168</volume>
            <issue>8</issue>
            <fpage>1015</fpage>
            <pub-id pub-id-type="pmid">12695387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wells</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Steed</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Zajko</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Webster</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Recognition and treatment of arterial insufficiency from cafergot.</article-title>
            <source>J Vasc Surg</source>
            <year>1986</year>
            <month>Jul</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-15</page-range>
            <pub-id pub-id-type="pmid">3723691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ibraheem</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Paalzow</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tfelt-Hansen</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1983</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>695</fpage>
            <page-range>695-9</page-range>
            <pub-id pub-id-type="pmid">6419759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skowronski</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Tronson</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Parkin</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of ergotamine poisoning with sodium nitroprusside.</article-title>
            <source>Med J Aust</source>
            <year>1979</year>
            <month>Jul</month>
            <day>14</day>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-9</page-range>
            <pub-id pub-id-type="pmid">502953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glazer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Ergot poisoning.</article-title>
            <source>Postgrad Med J</source>
            <year>1966</year>
            <month>Sep</month>
            <volume>42</volume>
            <issue>491</issue>
            <fpage>562</fpage>
            <page-range>562-8</page-range>
            <pub-id pub-id-type="pmid">5919182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miljkovi&#x00107;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smajlovi&#x00107;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tiri&#x00107; Campara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jurina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Duranovi&#x00107; Vinkovi&#x00107;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jankovi&#x00107;</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Begovi&#x00107;</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>&#x00106;erani&#x00107;</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The first comparative double-blind trial on efficacy and safety of ergotamine based five-component combination and sumatriptan in migraine without aura.</article-title>
            <source>Hippokratia</source>
            <year>2018</year>
            <season>Jan-Mar</season>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-22</page-range>
            <pub-id pub-id-type="pmid">31213753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Demaagd</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The pharmacological management of migraine, part 1: overview and abortive therapy.</article-title>
            <source>P T</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>7</issue>
            <fpage>404</fpage>
            <page-range>404-16</page-range>
            <pub-id pub-id-type="pmid">19750119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000d6;zt&#x000fc;rk</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Acute Treatment of Migraine.</article-title>
            <source>Noro Psikiyatr Ars</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>50</volume>
            <issue>Suppl 1</issue>
            <fpage>S26</fpage>
            <page-range>S26-S29</page-range>
            <pub-id pub-id-type="pmid">28360580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fichtel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Melin</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Relaxation treatment of adolescent headache sufferers: results from a school-based replication series.</article-title>
            <source>Headache</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>692</fpage>
            <page-range>692-704</page-range>
            <pub-id pub-id-type="pmid">15953302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37693.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaul</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Visscher</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Bhola</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sorbi</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Galli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Team players against headache: multidisciplinary treatment of primary headaches and medication overuse headache.</article-title>
            <source>J Headache Pain</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>511</fpage>
            <page-range>511-9</page-range>
            <pub-id pub-id-type="pmid">21779789</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
